Infigratinib (oral)
BridgeBio Pharma (BBIO)
Decision dateFeb 4, 2027
81 days away
Marketer take
An oral option in achondroplasia, where Voxzogo and Yuviwel are already approved, so expect route-of-administration messaging.
- Sponsor company
- BridgeBio Pharma (BBIO)
- Indication
- Achondroplasia
- Therapeutic area
- Endocrinology, Rare disease
- Event
- PDUFA target action date
- Date
- Feb 4, 2027
- Status
- Upcoming
- Source
- company press release
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?